Filtered By:
Specialty: Pharmaceuticals
Management: Hospitals
This page shows you your search results in order of date.
Order by Relevance | Date
Total 76 results found since Jan 2013.
AI Software to Detect Large Vessel Occlusion Cuts Workflow Time
THURSDAY, Sept. 21, 2023 -- Artificial intelligence (AI)-detected large vessel occlusion (LVO) ischemic stroke coupled with secure mobile phone application-based communication improves in-hospital acute ischemic stroke workflows, according to a...
Source: Drugs.com - Pharma News - September 21, 2023 Category: Pharmaceuticals Source Type: news
Wesley Medical Center certified as a comprehensive stroke center
Wesley is the only hospital in Kansas to hold the designation from DNV Healthcare.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - August 23, 2023 Category: Pharmaceuticals Authors: Shelby Kellerman Source Type: news
Disease Burden of Ischemic Stroke Predicted to Continue Increasing
FRIDAY, May 19, 2023 -- The disease burden of ischemic stroke increased from 1990 to 2019 and is predicted to continue increasing, according to a study published online May 17 in Neurology.
Jiahui Fan, from the Shanghai Fourth People ' s Hospital in...
Source: Drugs.com - Pharma News - May 19, 2023 Category: Pharmaceuticals Source Type: news
New VOYAGER PAD Analysis Confirms Consistent Benefit of XARELTO ® (rivaroxaban) Plus Aspirin Following Lower Extremity Revascularization (LER)
TITUSVILLE, NJ, March 5, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced data from a new prespecified analysis from the Phase 3 VOYAGER PAD clinical trial reinforcing the benefits of the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily plus aspirin 100 mg once daily) over standard of care (aspirin alone), demonstrating consistent benefit at 30 days, 90 days and up to three years following LER in patients with PAD. Lower extremity revascularization, also called peripheral revascularization, is a procedure that restores blood flow in blocked arteries or veins. This analysis of ...
Source: Johnson and Johnson - March 5, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
HCA Florida Bayonet Point Hospital names new C-level officer
HCA Florida Bayonet Point Hospital is a 290-bed, full-service acute care hospital that provides services such as a comprehensive stroke center and an advanced surgery center.
Source: bizjournals.com Health Care:Pharmaceuticals headlines - January 31, 2023 Category: Pharmaceuticals Authors: Devonta Davis Source Type: news
Real-World Study Confirms Benefit of XARELTO ® (rivaroxaban) for Secondary Prevention of Venous Thromboembolism in Cancer Patients
TITUSVILLE, NJ, December 9, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced observational data from eight years of clinical practice showing that the oral Factor Xa inhibitor XARELTO® (rivaroxaban) is associated with comparable effectiveness and safety to the Factor Xa inhibitor apixaban for the treatment of cancer-associated thromboembolism (CAT) in a broad cohort of patients with various cancer types. Patients with CAT are at a higher risk of venous thromboembolism (VTE), which is the second-leading cause of death in people with cancer.1Data from the Observational Study in Cancer-A...
Source: Johnson and Johnson - December 9, 2022 Category: Pharmaceuticals Tags: Latest News Source Type: news
Late-Breaking Data from Pivotal Phase 3 PRECISION Study Demonstrates Significant and Sustained Effect of Aprocitentan on Lowering Blood Pressure for Patients with Difficult-to-Control Hypertension
RARITAN, NJ, November 7, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson, in collaboration with Idorsia Ltd, today announced results from the Phase 3 PRECISION study, which found aprocitentan, an investigational, novel dual endothelin receptor antagonist (ERA), significantly reduced blood pressure (BP) and maintained the effect for up to 48 weeks when added to standardized combination background antihypertensive therapy in patients with difficult-to-control hypertension (sometimes referred to as resistant hypertension). These data were presented as a Late-Breaking Science presentation during the Amer...
Source: Johnson and Johnson - November 7, 2022 Category: Pharmaceuticals Source Type: news
Moderate-to-Heavy Drinking Linked to Stroke Risk in Young Adults
WEDNESDAY, Nov. 2, 2022 -- For young adults, moderate-to-heavy drinking is associated with an increased risk for stroke, according to a study published online Nov. 2 in Neurology.
Jae-wook Chung, M.D., from Seoul National University Hospital in...
Source: Drugs.com - Pharma News - November 2, 2022 Category: Pharmaceuticals Source Type: news
Biosense Webster Launches the OCTARAY ™ Mapping Catheter with TRUEref™ Technology
IRVINE, CA – September 6, 2022 – Biosense Webster, Inc., part of Johnson & Johnson MedTech[†], today announced the release of the OCTARAY™ Mapping Catheter with TRUEref™ Technology powered by the CARTO™ 3 Version 7 System. The OCTARAY™ Mapping Catheter was developed for the mapping of cardiac arrhythmias, including atrial fibrillation (AFib). The catheter has eight splines with improved electrode spacing options to provide shorter and more efficient mapping times than PENTARAYTM NAV ECO Mapping Catheter, which may shorten overall ablation procedure times.[2],[8],[‡] AFib is the most common type of cardi...
Source: Johnson and Johnson - September 6, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
Daytime Napping Frequency Linked to HTN, Ischemic Stroke Risks
MONDAY, July 25, 2022 -- Increased frequency of daytime napping might be a potential causal risk factor for hypertension and ischemic stroke, according to a study published online July 25 in Hypertension.
Min-jing Yang, from Xiangya Hospital in...
Source: Drugs.com - Pharma News - July 25, 2022 Category: Pharmaceuticals Source Type: news
Gaps ID ' d in Hospitals ' Likelihood of Adopting Stroke Care Certification
WEDNESDAY, July 6, 2022 -- Hospitals in low-income and rural communities have a lower likelihood of receiving stroke care certification, according to a study published online June 27 in JAMA Neurology.
Yu-Chu Shen, Ph.D., from the Naval...
Source: Drugs.com - Pharma News - July 6, 2022 Category: Pharmaceuticals Source Type: news
Exposure to Air Pollution May Increase In-Hospital Stroke-Related Deaths
THURSDAY, May 26, 2022 -- Short-term and long-term exposure to particulate matter (PM) pollution is a risk factor for in-hospital stroke-related death, according to a study published online May 25 in Neurology.
Miao Cai, Ph.D., from Sun Yat-sen...
Source: Drugs.com - Pharma News - May 26, 2022 Category: Pharmaceuticals Source Type: news
Mayo Clinic in Arizona receives comprehensive stroke center certification
PHOENIX — Mayo Clinic Hospital in Phoenix announces that it has received certification from DNV as a comprehensive stroke center, reflecting the highest level of competence for treatment of serious stroke events. The DNV Comprehensive Stroke Center Certification is based on standards set forth by the Brai n Attack Coalition and the American Stroke Association, and affirms that the medical center addresses the full spectrum of stroke care – diagnosis, treatment, rehabilitation and education – and…
Source: Mayo Clinic Business News - May 24, 2022 Category: Pharmaceuticals Source Type: news
New Data From Two Large Studies Reinforce Effectiveness of Dual Pathway Inhibition (DPI) with XARELTO ® (rivaroxaban) Plus Aspirin in Patients with Coronary Artery Disease (CAD) and/or Peripheral Artery Disease (PAD)
RARITAN, N.J., May 23, 2022 – Findings from the XARELTO® (rivaroxaban) Phase 3 COMPASS Long-Term Open Label Extension (LTOLE) study and the XARELTO® in Combination with Acetylsalicylic Acid (XATOA) registry have been published in the European Society of Cardiology’s (ESC) European Heart Journal, Cardiovascular Pharmacotherapy. Additionally, the XATOA registry was presented at the American Congress of Cardiology’s 71st Annual Scientific Session (ACC.22). These studies provide further evidence supporting the role of dual pathway inhibition (DPI) with the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 100 mg...
Source: Johnson and Johnson - May 23, 2022 Category: Pharmaceuticals Source Type: news
Pennsylvania Senate Candidate John Fetterman Released From Hospital After Stroke
Pennsylvania ’s lieutenant governor won the Democratic primary for Pennsylvania’s open Senate seat while receiving treatment in the hospital.
Source: Forbes.com Healthcare News - May 22, 2022 Category: Pharmaceuticals Authors: Carlie Porterfield, Forbes Staff Tags: Lifestyle /lifestyle Innovation /innovation Healthcare /healthcare Breaking breaking-news consumer Source Type: news
